Detection of hypoxia in human squamous cell carcinoma by EF5 binding

Cancer Research

Volumn 60, Issue 7, 2000, Pages 2018-2024

  Evans, Sydney M ^a   Hahn, Stephen ^a   Pook, Deirdre R ^a   Jenkins, W Timothy ^a   Chalian, Ara A ^a   Zhang, Paul ^a   Stevens, Craig ^b   Weber, Randall ^a   Weinstein, Gregory ^a   Benjamin, Ivor ^a   Mirza, Natasha ^a   Morgan, Mark ^a   Rubin, Steven ^a   McKenna, W Gillies ^a   Lord, Edith M ^c   Koch, Cameron J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE;

ADULT; AGED; ARTICLE; CELL HYPOXIA; CLINICAL ARTICLE; DRUG BINDING; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BINDING SITES; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; ETANIDAZOLE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYDROCARBONS, FLUORINATED; MALE; MIDDLE AGED; UTERINE CERVICAL NEOPLASMS;

EID: 0034029848     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kolstad, P. Vascularization, oxygen tension and radiocurability in cancer of the cervix. Universitetsforlaget. Oslo, Norway: Oslo, 1964.
2. Schreiner, P., Siracka, E., Siracky, J., and Manka, I. The effect of anemia on the radiotherapy results of the uterine cervix cancer. Neoplasma (Bratisl.), 22: 655-660, 1975.
3. Bush, R. S., Jenkins, R. D. T., Allt, W. E. C., Beale, F. A., Bean, H., Dembo, A. J., and Pringle, J. F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer, 37: 302-306, 1978.
4. Fein, D. A., Lee, W. R., Hanlon, A. L., Ridge, J. A., Langer, C. J., Curran, W. J., Jr., and Coia, L. R. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J. Clin. Oncol., 13: 2077-2083, 1995.
5. Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J., Hartz, W. H., and Broder, G. J. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol., Phys., 14: 831-838, 1988.
6. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., and Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 56: 4509-4515, 1996.
7. 2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol., 26: 45-50, 1993.
8. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., and Dewhirst, M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys., 38: 285-289, 1997.
9. Nordsmark, M., Overgaard, M., and Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol., 41: 31-39, 1996.
10. Fyles, A. W., Milosevic, M., Wong, R., Kavanagh, M. C., Pintilie, M., Sun, A., Chapman, W., Levin, W., Manchul, L., Keane, T. J., and Hill, R. P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol., 48: 149-156, 1998.
11. Olive, P., Banath, J., and Durand, R. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "Comet" assay. Radiat. Res., 122: 86-94, 1990.
12. Raleigh, J. A., Miller, G. G., Franko, A. J., Koch, C. J., Fuciarelli, A. F., and Kelley, D. A. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br. J. Cancer, 56: 395-400, 1987.
13. Chapman, J. D. The detection and measurement of hypoxic cells in solid tumors. Cancer (Phila.), 54: 2441-2449, 1984.
14. Evans, S. M., Joiner, B., Jenkins, W. T., Laughlin, K. M., Lord, E. M., and Koch, C. J. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]. Br. J. Cancer, 72: 875-882, 1995.
15. Lord, E. M., Harwell, L., and Koch, C. J. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res., 53: 5271-5276, 1993.
16. Siim, B., Menke, D., Dorie, M., and Brown, J. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res., 57: 2922-2928, 1997.
17. Franko, A. J., Koch, C. J., Garrecht, B. M., Sharplin, J., and Hughes, D. Oxygen dependence of binding of misonidazole to rodent and human tumors in vitro. Cancer Res., 47: 5367-5376, 1987.
18. Cline, J. M., Thrall, D. E., Page, R. L., Franko, A. J., and Raleigh, J. A. Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours. Br. J. Cancer, 62: 925-931, 1990.
19. Hodgkiss, R. J., Jones, G., Long, A., Parrick, J., Smith, K. A., Stratford, M. R. L., and Wilson, G. D. Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection. Br. J. Cancer, 63: 119-125, 1991.
20. Koh, W. J., Rasey, J. S., Evans, M. L., Grierson, J. R., Lewellen, T. K., Graham, M. M., Krohn, K. A., and Griffin, T. W. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int. J. Radiat. Oncol. Biol. Phys., 22: 199-212, 1992.
21. Olive, P. L., and Durand, R. E. Fluorescent nitroheterocycles for identifying hypoxic cells. Cancer Res., 43: 3276-3280, 1983.
22. Raleigh, J. A., Zeman, E. M., Rathman, M., LaDine, J. K., Cline, J. M., and Thrall, D. E. Development of an ELISA for the detection of 2-nitroimidazole hypoxia markers hound to tumor tissue. Int. J. Radiat. Oncol. Biol. Phys., 22: 403-405, 1992.
23. Raleigh, J. A., Calkins-Adams, D. P., Rinker, L. H., Ballenger, C. A., Weissler, M. C., Fowler, W. C., Jr., Novotny, D. B., and Varia, M. A. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res., 58: 3765-3768, 1998.
24. Coleman, C. N., Wasserman, T. H., Urtasun, R. C., Halsey, J., Noll, L., Hancock, S., and Phillips, T. L. Final report of the Phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole). Radiation Therapy Oncology Group 83-03. Int. J. Radiat. Oncol. Biol. Phys., 18: 389-393, 1990.
25. Laughlin, K. M., Evans, S. M., Jenkins, W. T., Tracy, M., Chan, C. Y., Lord, E. M., and Koch, C. J. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl)acetamide) in mice bearing subcutaneous EMT6 tumors. J. Pharmacol. Exp. Ther., 277: 1049-1057, 1996.
26. Koch, C. J., Evans, S. M., and Lord, E. M. Oxygen dependence of cellular uptake of EF5[2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies versus bound radioactivity. Br. J. Cancer, 72: 869-874, 1995.
27. Thomlinson, R. H., and Gray, L. H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer, 9: 539-579, 1955.
28. Wouters, B. G., and Brown, J. M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiation therapy. Radiat. Res., 147: 541-550, 1997.
29. Evans, S. M., Jenkins, W. T., Joiner, B., Lord, E. M., and Koch, C. J. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res., 56: 405-411, 1996.
30. Jenkins, W., Evans, S., and Koch, C. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode. Int. J. Radiat. Oncol. Biol. Phys., in press, 2000.
31. Lee, J., Fenton, B. M., Koch, C. J., Frelinger, J. G., and Lord, E. M. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res., 58: 1478-1485, 1998.
32. Evans, S. M., Jenkins, W. T., Shapiro, M., and Koch, C. J. Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status. Adv. Exp. Med. Biol., 411: 215-225, 1997.
33. Gross, M. W., Karbach, U., Groebe, K., Franko, A. J., and Mueller-Klieser, W. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int. J. Cancer, 61: 567-573, 1995.
34. Cline, J. M., Rosner, G. L., Raleigh, J. A., and Thrall, D. E. Quantification of CCI-103F labeling heterogeneity in canine solid tumors. Int. J. Radiat. Oncol. Biol. Phys., 37: 655-662, 1997.
35. Kennedy, A. S., Raleigh, J. A., Perez, G. M., Calkins, D. P., Thrall, D. E., Novotny, D. B., and Varia, M. A. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int. J. Radiat. Oncol. Biol. Phys., 37: 897-905, 1997.
36. Wilson, D., Laughlin, K., Rozanov, C., Mokashi, A., Vinogradov, S., Lahiri, S., Koch, C., and Evans, S. Tissue oxygen sensing and the carotid body. Adv. Exp. Med. Biol., 454: 447-454, 1998.
37. Rasey, J. S., Koh, W. J., Evans, M. L., Peterson, L. M., Lewellen, T. K., Graham, M. M., and Krohn, K. A. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int. J. Radiat. Oncol. Biol. Phys., 36: 417-428, 1996.